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Abstract
Background: Antimicrobial treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
remains controversial. In some cases AECOPD are caused by microorganisms that are resistant to treatments
recommended by guidelines. Our aims were: 1) identify the risk factors associated with infection by microorganisms
resistant to conventional treatment (MRCT), 2) Compare the clinical characteristics and outcomes of patients with
AECOPD resulting from MRCT against those with AECOPD from other causes.
Methods: We prospective analysed a cohort of patients admitted with severe AECOPD (2009 to 2015) who were
assigned to three groups: patients with MRCT (those patients with germs resistant to antibiotics recommended in
guidelines), patients with microorganisms sensitive to conventional antimicrobial treatment (MSCT), and patients
with negative microbiology results who had not previously received antibiotics. Multinomial logistic regression
analyses were used to examine the associations between microbial aetiology groups and risk factors. The
association between LOS and risk factors was also tested in simple and multiple analyses, and similar inclusion
criteria were applied for the linear regression analysis.
Results: Of the 451 patients admitted, 195 patients (43%) were included. Respiratory cultures were positive in
86(44%) and negative in 109(56%). MRCT were isolated in 34 cases (40%) and MSCT in 52 (60%). Patients with MRCT
had more AECOPD in the previous year, received more antibiotic treatment in the previous three months, had more
severe disease, higher dyspnoea and a positive respiratory culture in the previous year (mainly for Pseudomonas
aeruginosa). The following conditions were independent factors for MRCT isolation: non-current smoker (odds ratio
[OR] 4.19 [95% confidence interval [CI] 1.29–13.67], p = 0.017), ≥ 2 AECOPD or ≥ 1 admission for AECOPD in the previous
year (OR 4.13 [95% CI 1.52–11.17], p = 0.005), C-reactive protein < 5 mg/dL; (OR 3.58 [95% CI 1.41–9.07], p = 0.007).
Mortality rates were comparable at 30-days, one year and 3 years; however, patients in the MRCT group had longer
hospital stays.
Conclusion: In conclusion, there are risk factors for resistant germs in AECOPD; however, the presence of these germs
does not increase mortality. Patients with isolation of MRCT had longer length of stay.
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Background
Acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) negatively affect hospitalisation, re-
admission, disease progression and mortality rates in pa-
tients with COPD [1]. Severe AECOPD are mainly
triggered by bacterial infection, viral infection or environ-
mental agents, with the most common causes of bacterial
infection being Streptococcus pneumoniae, Haemophilus
influenzae and Moraxella catarrhalis [2–4]. Thus, current
recommendations for antimicrobial treatment are amino-
penicillin with or without clavulanic acid, a macrolide or a
tetracycline [5, 6]. AECOPD are infrequently caused
by microorganisms—such as Pseudomonas aeruginosa,
methicillin-resistant Staphylococcus aureus (MRSA),
Stenotrophomonas maltophilia or enterobacteria—that
are resistant to these treatments. Guidelines and previous
studies of severe AECOPD suggest that these patients
have increased frequencies of exacerbations, previous anti-
biotic use, previous hospital admissions and more severe
airflow limitations [2, 5, 7, 8].
At least 30% of COPD patients are colonised by a po-
tential pathogen when in a stable phase of their disease;
however only 0.5% are colonised by Enterobacteriaceae,
P. aeruginosa or S. maltophilia [9]. Also, AECOPD are
associated with the overgrowth of potential pathogens
and with the occurrence of P. aeruginosa in the lower
airway [10]. Knowing the risk factors to microorganisms
resistant to conventional antibiotic treatment (MRCT)
in AECOPD could lead to improved prophylaxis and
empirical antimicrobial treatment.
We hypothesised that specific factors predict the pres-
ence of MRCT. Our primary aim was to identify the risk
factors associated with infection by MRCT. Our second-
ary aim was to compare the clinical characteristics and
outcomes of patients with AECOPD resulting from
MRCT against those with AECOPD from other causes.
Methods
Study design and patients selection
This observational cohort study was performed between
January 2009 and December 2015, and included all
patients admitted with a diagnosis of AECOPD to the
Respiratory Department of the Hospital Clinic, Barcelona,
Spain. COPD was defined according to the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) guide-
lines [5], with spirometry performed in a stable disease
phase and at least six months prior to hospital admission.
Patients with a smoking history of 10 pack-years were
considered positive smokers. A worsening of respiratory
symptoms compared with the preceding days, and which
required a change in home care medication, was used as a
clinical definition for AECOPD [5, 11]. Exacerbation se-
verity was based on the respiratory symptoms/signs and
the presence of potential indications for hospitalisation
[5]. The exclusion criteria were: 1) documented history of
asthma or bronchiectasis as the predominant illness and
2) clinical pneumonia or acute heart failure identified
at admission.
Ethics approval and consent to participate
The study protocol was approved by the Hospital Research
and Ethics Committee (CEIC 2008/4106) and the study
was conducted in accordance with good clinical practice
guidelines and the declaration of Helsinki. Written in-
formed consent was obtained from all enrolled patients.
Microbiological evaluation
Sputum samples were obtained at admission for bacter-
ial culture, before starting antibiotic therapy. Routine
antimicrobial susceptibility testing included the disc dif-
fusion method or E-test for P. aeruginosa. The results of
susceptibility testing were interpreted according to the
European Committee on Antimicrobial Susceptibility
Testing guidelines [12]. Multidrug-resistant (MDR), ex-
tensively drug resistant (XDR) and pan-drug resistant
bacteria were categorised according to criteria set out by
Magiorakos et al. [13]. The quality of sputum samples
was assessed using the Murray and Washington scoring
system. Patients with poor quality sputum samples (> 10
epithelial cells or < 25 leucocytes) were excluded from
analysis [14]. Patients with mycobacterial, fungal isola-
tion (e.g., Aspergillus or Candida) or Nocardia spp. were
also excluded.
Patients were classified into 3 groups: 1) patients with
the isolation of microorganism sensitive to conventional
treatment (MSCT) according to GOLD guidelines (i.e.,
aminopenicillin with clavulanic acid, a macrolide or a
tetracycline); 2) patients with MRCT isolation, (i.e., P.
aeruginosa, MRSA, S. maltophilia, Enterobacteriaceae
producer of extended spectrum of beta lactamase and
Acinetobacter baumannii); and 3) patients with negative
microbiology results who did not receive antibiotics in
the 7 days previous at admission.
Previous antibiotic treatment was not considered as
inclusion/exclusion criteria in MRCT or MSCT groups.
Nobody patient used macrolide as chronic treatment,
thus it was not considered as variable.
Clinical measurements and outcomes
Demographic variables, body mass index (BMI), smok-
ing history (former smoker was considered as those pa-
tients who quit smoke more than 12 months), presence
of co-morbidities measured by Charlson index [15],
baseline dyspnoea grade based in modified medical re-
search council (mMRC), COPD severity score measured
by a questionnaire (COPDSS) [16] and BODEx index
(i.e., BMI, airflow obstruction, dyspnoea and exacerba-
tions) [17], use of long-term oxygen therapy (LTOT) and
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use of domiciliary medications (i.e., inhaled bronchodila-
tors, such as short-acting β2 agonist [SABA], long-acting
β2 agonist [LABA], anticholinergics or inhaled cortico-
steroids) were recorded at hospital admission. Character-
istics of any exacerbations during the previous year, any
previous antibiotic treatment (3 months before admis-
sion) and any microorganism isolated in the previous
year were also recorded. Vital signs (body temperature,
respiratory rate, heart rate and blood pressure) were
assessed at admission. Arterial blood gases and labora-
tory parameters (i.e., leukocytes, haematocrit, haemoglo-
bin, C-reactive protein, glucose and creatinine) were
recorded at admission and at day 3.
Variables relating to clinical progression included
length of hospital stay (LOS), use of non-invasive mech-
anical ventilation (NIMV), use of invasive mechanical
ventilation (IMV) and intensive care unit (ICU) admis-
sion during the initial hospitalisation. Data on prognosis
(cumulative number of deaths for all-causes and time to
death) were recorded at 30 days, 1 year and 3 years.
Statistical analysis
We report the number and percentage of patients for
categorical variables and the median and interquartile
range (IQR) for continuous variables. Categorical vari-
ables were compared using the chi-square test, and con-
tinuous variables were compared by one-way analysis of
variance or the nonparametric Kruskal–Wallis test.
Post-hoc pairwise comparisons were carried out via the
Bonferroni method to control for the experiment-wise error
rate. Survival curves were obtained using the Kaplan–Meier
method and compared using the Gehan-Breslow-Wilcoxon
test. Patients lost to follow-up were censored in the
survival analysis.
Multinomial logistic regression analyses were used to
examine the associations between microbial aetiology
groups (i.e., MRCT or MSCT relative to unknown aeti-
ology) and risk factors (i.e., baseline characteristics and
clinical presentation). Variables were included in the
multivariate model when univariate comparisons yielded
a level of significance of p < 0.05 due the limited number
of patients in the MRCT and MSCT groups and in order
to exclude bias related to overestimation or underesti-
mation of regression coefficient variance. The final
multivariate model was calculated in a stepwise forward
selection procedure (pin = 0.05, pout = 0.10). To identify
the problem of collinearity, we calculated the r coeffi-
cient of 2 variables; that is, if 2 independent variables
were highly correlated (r > | ± 0.30|), the variable with
the largest variance was excluded from the multivariate
analysis [18]. The association between LOS and risk fac-
tors was also tested in simple and multiple analyses, and
similar inclusion criteria were applied for the linear
regression analysis (p < 0.05). The odds ratios (ORs) or
beta coefficients (βs) and their 95% confidence intervals
(CIs) were estimated. The Cox and Snell R2 and the
Nagelkerke R2 were calculated to assess the overall fit of
the multinomial logistic regression model and the R2 for
the linear regression model. The area under the receiver
operating characteristic (ROC) curve of the multivariate
model to predict MRCT was calculated. Internal valid-
ation of the prediction models was conducted using or-
dinary nonparametric bootstrapping with 1000 bootstrap
samples and bias-corrected, accelerated, 95% CIs [19].
The same logistic regression analyses for microbial aeti-
ology groups were also performed but using a multi-
nomial logistic regression model for MRCT with only P.
aeruginosa or MSCT relative to negative microbiology.
We investigated the missing data patterns for covari-
ates, assumed missing at random [20], and used multiple
imputation [21] to generate 5 datasets to evaluate the
prediction performance for the microbial aetiology
group. The model for multiple imputation included all
covariates of the risk models as well as the microbial
aetiology group. For simplicity, in the evaluation of the
performance we filled in missing values with the first set
of imputed values from the multiple imputation.
The level of significance was set at 0.05 (two-tailed).
All analyses were performed with IBM SPSS Statistics
23.0 (Armonk, New York).
Results
Patient characteristics
Of the 451 patients admitted with an AECOPD during
the observation period, 256 (57%) were excluded. The
study population therefore comprised 195 patients
(43%), of which 86 (44%) had positive respiratory cul-
tures and 109 (56%) had negative microbiology and no
history of previous antibiotic therapy (Fig. 1). AECOPD
was associated with MRCT isolation in 34 cases (40%),
and other pathogens were isolated in the remaining 52
cases (60%).
Compared with the other groups, patients with MRCT
tended to be non-current smokers, have more AECOPD
episodes in the previous year, have more hospital admis-
sions in the previous year, receive more antibiotic treat-
ments in the previous 3 months and have more severe
disease (higher mMRC dyspnoea grades, higher BODEx
indexes and higher COPDSS values) (Table 1). No differ-
ences were observed at baseline in purulent sputum,
Anthonisen AECOPD classification or pulmonary gas
exchange. A higher percentage of patients with MRCT
had a positive respiratory culture in the previous year,
mainly for P. aeruginosa.
Microbiological findings
In the group of patients with MRCT, the most frequent
pathogen was P. aeruginosa (25 patients [74%]). Two
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patients had methicillin-resistant S. aureus, one patient
S. maltophilia, another had A. baumannii and 5 had
polymicrobial aetiology (Fig. 2 and Additional file 1:
Table S1). In total, 9 patients (50%) with previous P. aer-
uginosa isolation had received effective treatment.
Among the patients with MSCT, S. pneumoniae and H.
influenzae were the most common pathogens (35 and
31%, respectively), but 2 patients had Enterobacteriaceae
(Klebsiella spp. and Serratia spp.) that were sensitive to
aminopenicillins (Fig. 2). P. aeruginosa isolates were
categorised as MDR in 10 cases (40%) and XDR in 3
cases (12%).
Antibiotic treatment
Data on antibiotic treatment were available for 163
patients (88%). The most frequent regimen was fluoro-
quinolone monotherapy (n = 82; 50%), penicillin mono-
therapy (n = 27; 17%) and antibiotic combination therapy
(n = 44; 27%). The group with MRCT received more
combination therapy (p = 0.003) and less fluoroquino-
lone monotherapy (p = 0.012) compared with the other 2
groups. The most frequent used combinations were
β-lactam plus macrolide in the MSCT group and fluoro-
quinolones based combinations in the MRCT group.
Empirical antimicrobial treatment was inadequate in 20
cases with positive microbiology (24%), of which 15
(44%) and 5 (10%) were among patients with MRCT and
MSCT, respectively (p < 0.001).
Risk factors for MRCT and MSCT
The following risk factors showed significant associa-
tions with the microbial aetiology groups in individual
multinomial logistic regression, and were thus used for
the initial multivariate model: smoker status, ≥2
AECOPD episode or ≥ 1 AECOPD admission in the pre-
vious year, bronchiectasis, LTOT, BODEx index and
C-reactive protein (data not shown). The results of the
multivariate model are displayed in Table 2. The model
shows that the OR for MRCT isolation was significantly
increased if the patients was a non-current smoker, had
≥2 AECOPD episodes or ≥ 1 AECOPD admission in the
previous year and had a low systemic inflammatory
Fig. 1 Flowchart
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response. The OR for MSCT isolation, however, was
strongly decreased with a high BODEx index (4th quar-
tile) (Table 3). The AUC was 0.80 (95% CI, 0.72–0.87)
for the model predictive of MRCT isolation (Fig. 3). The
data for internal validation of the logistic regression
model (using bootstrapping with 1000 samples) are
Table 1 Patient characteristics
Variable Patients with microorganisms
resistant to conventional
treatment (n = 34)
Patients with microorganisms
sensitive to conventional




Age, mean (SD), years 73 (10) 71 (10) 71 (11) 0.546
Male sex, n (%) 29 (85) 43 (83) 91 (83) 0.950
BMI, mean (SD), Kg/m2 28 (5) 27 (5) 27 (5) 0.756
Current smoker, n (%) 4 (12)b,c 21 (40)a 43 (39)a 0.008
Packs/year, median (IQR) 33 (30; 90) 50 (40; 60) 60 (50; 95) 0.043
AECOPD in the previous year, n (%) 25 (74)c 25 (48) 41 (38)a 0.001
≥2 AECOPD in the previous year, n (%) 16 (47)c 16 (31) 19 (18)a 0.003
Admissions by AECOPD in the previous year, n (%) 20 (59)c 17 (33) 28 (26)a 0.002
≥ 2 AECOPD or ≥ 1 admission for AECOPD in the
previous year, n (%)
24 (71)b,c 21 (40) 32 (30)b <0.001
Prior antibiotic treatment (last 3 months), n (%) 26 (79)b,c 22 (43)a,c 22 (21)a,b <0.001
Prior antibiotic treatment, n (%) 9 (27) 14 (27) 0 (0) <0.001
Inhaled corticosteroids use, n (%) 17 (50) 19 (41) 35 (38) 0.480
Bronchiectasis, n (%) 13 (48) 10 (28) 29 (38) 0.251
Long-term oxygen therapy, n (%) 18 (53)c 15 (29) 31 (28)a 0.023
Charlson index, median (IQR) 2 (1; 3) 2 (1; 3) 2 (1; 3) 0.459
BODEx index, median (IQR) 3 (0; 6)c 0 (0; 4.5) 0 (0; 0)a 0.001
mMRC Dyspnoea, median (IQR) 3 (2; 3)b,c 2 (1; 3)a 2 (1; 3)a <0.001
COPDSS, median (IQR) 19 (14; 21)b,c 15 (9; 19)a 13 (8; 18)a <0.001
FEV1, median (IQR), % ref 33 (27; 41) 45 (31; 55) 39 (28; 57) 0.073
FEV1 < 35% ref., n (%) 17 (55) 13 (28) 39 (41) 0.064
Positive sputum cultures in the previous year, n (%) 18 (53)b,c 12 (23)a 11 (10)a <0.001
Pseudomonas aeruginosa in the previous year, n (%)d 8 (44) 1 (8) 1 (9) 0.048
Respiratory rate, mean (SD) 22 (20; 26) 22 (20; 28) 24 (20; 26) 0.423
Anthonisen classification, n (%) 0.793
Type I 17 (52) 20 (40) 42 (40)
Type II 9 (27) 19 (38) 38 (36)
Type III 7 (21) 11 (22) 25 (24)
Purulent sputum, n (%) 18 (55) 18 (36) 41 (39) 0.203
Haemoglobin, median (IQR), gr/L 134 (120; 146) 142 (127; 151) 139 (124; 153) 0.159
pH, median (IQR) 7.40 (7.36; 7.45) 7.39 (7.34; 7.43) 7.39 (7.35; 7.43) 0.907
PaCO2, median (IQR), mmHg 49 (42; 61) 44 (38; 58) 45 (38; 58) 0.340
PaO2/FiO2, median (IQR), mmHg 257 (230; 321) 248 (207; 293) 267 (232; 311) 0.490
C-reactive protein, median (IQR), mg/dL 2.5 (1.5; 5.4) 5.4 (1.5; 17.4) 4.9 (1.6; 12.8) 0.113
Abbreviations: AECOPD acute exacerbation of chronic obstructive pulmonary disease, BMI body mass index, BODEx body mass index, airflow obstruction, dyspnoea
and exacerbations, COPDSS chronic obstructive pulmonary disease severity score, FEV1 forced expiratory volume in the 1st second, IQR interquartile range,
mMRC modified medical research council, SD standard deviation
Data are shown as number and percentage of patients, mean (SD), or median (1st quartile; 3rd quartile)
Percentages are calculated on non-missing data
aP < 0.05 vs. Patients with microorganisms resistant to conventional treatment
bp < 0.05 vs. Patients with microorganisms sensitive to conventional treatment
cp < 0.05 vs. Patients with negative microbiology
dPercentages calculated for patients with positive sputum cultures in the previous year
Bold Italic entries indicate statistical significance
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presented in Additional file 1: Table S2. The variables in-
cluded in the model demonstrated robust results, with
small 95% CIs around the original coefficients. When
differentiating MRCT with and without P. aeruginosa,
previous isolation of P. aeruginosa was the most
important predictor of P. aeruginosa isolation (Additional
file 1: Table S3, Table S4 and Figure S1).
Outcomes
Patients with MRCT had longer median hospital stays
than the other 2 groups (9 days [7–14] vs. 8 days [6–10]
in both cases, respectively; p = 0.026) (Table 3). No
differences were observed in ICU admission, IMV or
NIMV rates among the groups. Mortality rates were
comparable at 30-days, one year and 3 years, and the
number of AECOPD after discharge did not differ
among the groups. The Kaplan-Meier survival curves
depicting the 3-year mortality rates as a function of the
3 microbial aetiology groups are shown in Fig. 4. No dif-
ferences were observed when comparing patients with
adequate and inadequate empiric antibiotic treatment in
each group (MRCT and MSCT) or in overall population
(Additional file 1: Table S5).
The simple linear regression analysis revealed several
variables significantly associated with length of hospital
stay (Table 4). BODeX index, CRP levels, requirement of
mechanical ventilation (invasive or non-invasive) and
isolation of MRCT were those independently
Fig. 2 Microbial aetiology. Panel a Microorganisms Resistant to Conventional Treatment (n = 34). Panel b Patients with Microorganisms Sensitive
to Conventional Treatment (n = 52). Polymicrobial Isolation includes: 3 Pseudomonas aeruginosa, 2 Stenotrophomonas maltophilia, 1 Staphylococcus
aureus, 3 Streptococcus pneumoniae, 1 other. Others isolation include: 3 Corynebacterium spp., 2 Pasteurella spp., 1 Capnocytophaga spp.
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associated with length of hospital stay in the multiple
analyses. The data for internal validation of the linear
regression model (using bootstrapping with 1000
samples) are presented in Additional file 1: Table S8.
The variables included in the model demonstrated
robust results, with small 95% CIs around the original
coefficients.
Patients with P. aeruginosa isolation in the MRCT
group had higher hospital stays than patients without P.
aeruginosa in the same group. Patients with isolation of
MDR or XDR P. aeruginosa had the longest stays, but
there was no difference in mortality (Additional file 1:
Table S3, Table S4, Figure S1). The 3-year mortality
among patients with < 2 AECOPD episodes and no
admissions for AECOPD in the previous year differed
significantly between groups in the Kaplan-Meier ana-
lysis (p = 0.019; Additional file 1: Figure S2).
Discussion
In our study, we analysed 3 well-characterised groups,
comparing patients with MRCTs against controls groups
of patients with MSCTs and patients with negative
Table 2 Multinomial logistic regression model for microorganisms resistant to conventional treatment or microorganisms sensitive
to conventional treatment relative to negative microbiology
Variable Patients with microorganisms resistant to
conventional treatment
Patients with microorganisms sensitive to
conventional treatment
OR 95% CI P value OR 95% CI P value
Non-current smoker 4.19 1.29 to 13.67 0.017 0.78 0.38 to 1.59 0.49
≥ 2 AECOPD or 1 admission by AECOPD in the previous year 4.13 1.52 to 11.17 0.005 1.75 0.76 to 3.99 0.19
BODEx index
1st quartile: 0–2 1 – – 1 – –
2nd quartile: 3–4 2.32 0.67 to 7.98 0.18 0.62 0.21 to 1.88 0.40
3rd quartile: 5–6 1.85 0.58 to 5.90 0.30 1.12 0.44 to 2.88 0.82
4th quartile: 7–9 0.48 0.10 to 2.33 0.37 0.14 0.03 to 0.70 0.016
C-reactive protein < 5 mg/dL at admission 3.58 1.41 to 9.07 0.007 1.14 0.57 to 2.27 0.72
Abbreviations: AECOPD indicates acute exacerbation of chronic obstructive pulmonary disease exacerbation, BODEx body mass index, airflow obstruction, dyspnoea
and exacerbations, CI confidence interval, OR odds ratio
Data are shown as estimated ORs (95% CIs) of the explanatory variables observed at admission of patients in the microorganisms resistant to conventional
treatment (MRCT) and microorganisms sensitive to conventional treatment (MSCT) groups. The OR is defined as the probability of membership of the groups
MRCT or MSCT divided by the probability of membership of the negative microbiology group
The P value is based on the null hypothesis that all ORs relating to an explanatory variable equal unity
Model characteristics: likelihood ratio X2 test, p = 0.48; R2 coefficients = 0.21 (Cox and Snell), 0.24 (Nagelkerke)
Table 3 Clinical outcomes
Patients with microorganisms
resistant to conventional
treatment (n = 34)
Patients with microorganisms
sensitive to conventional
treatment (n = 52)
Patients with negative
microbiology (n = 109)
P value
AECOPD after 30 days of discharge, n (%) 24 (73) 21 (47) 57 (56) 0.070
Number of AECOPD after 30 days of discharge,
median (IQR)
1 (0; 3) 0 (0; 2) 1 (0; 1) 0.075
Time to the next AECOPD, median (IQR), days 39 (19; 170) 52 (27; 166) 86 (26; 182) 0.577
Length of stay, median (IQR), days 9 (7; 14)c 8 (6; 10.5) 8 (6; 10)a 0.026
ICU admission, n (%) 4 (12) 6 (12) 12 (11) 0.981
IMV, n (%) 2 (6) 1 (2) 3 (2) 0.564
NIMV, n (%) 6 (18) 10 (19) 16 (15) 0.780
30-day mortality, n (%) 1 (3) 1 (2) 4 (4) 0.834
1-year mortality, n (%) 11 (32) 12 (23) 19 (17) 0.173
3-years mortality, n (%) 16 (59) 19 (56) 40 (43) 0.211
Abbreviations: AECOPD indicates acute exacerbation of chronic obstructive pulmonary disease exacerbation, ICU intensive care unit, IMV invasive mechanical
ventilation, IQR interquartile range, NIMV non-invasive mechanical ventilation. Data are shown as number of patients (%), or median (1st quartile; 3rd quartile).
Percentages are calculated on non-missing data. aP < 0.05 vs. patients with microorganisms resistant to conventional treatment. bp < 0.05 vs. patients with
microorganisms sensitive to conventional treatment. cp < 0.05 vs. patients with negative microbiology
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microbiology and no previous antibiotic use. Our ana-
lyses revealed that not currently smoking, ≥ 2 AECOPD
episodes or ≥ 1 admission for AECOPD in the last year,
and a low systemic inflammatory response at admission
were independent risk factors for AECOPD caused by
an MRCT. However, although patients with MRCT had
longer hospital stays, they did not have higher mortality
or more severe AECOPD than the control groups. At
baseline, patients with MRCT had more severe disease,
as measured by the dyspnoea scale, COPDSS scale,
BODEx index and history of previous AECOPD. There
were no differences in symptoms or pulmonary gas ex-
change features at admission.
AECOPD are events that mark disease progression,
and as taken into account by the GOLD guidelines [5],
are as important as airflow limitation. Indeed, it is evi-
dent that there are patients who are susceptible to fre-
quent exacerbations, and in these, the most important
predictor of future episodes is the history of AECOPD
[22]; however, the association with microbiologic data
has been poorly analysed to date.
A low systemic inflammatory response was a risk factor
for MRCT isolation in this study, which could be due to
lower virulence or reduced ability to produce acute phase
reactants in the presence of these microorganisms. Similar
results were observed in patients with community
Fig. 3 Receiver operating characteristic curve for multinomial
logistic regression model to predict MRCT isolation. Abbreviations:
AUC indicates area under the curve; CI, confidence interval
Fig. 4 Kaplan–Meier analysis of the effect of microbial aetiology groups on time to death
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acquired pneumonia or ventilator associated pneumonia
in whom P. aeruginosa was isolated [23, 24].
There was also an association between smoking status
and MRCT isolation, specifically in favour of
non-current smoking status. It is known that smoke in-
creases upper respiratory tract colonisation of S. pneu-
moniae, H. influenzae, M. catarrhalis and Streptococcus
pyogenes [25], and that smoking facilitates colonisation
of the lung with these bacteria [9]. This is probably re-
lated to the decreased phagocytic ability of alveolar mac-
rophages and the decreased cytokine response associated
with smoking [26, 27]. The association between smoking
status and MRCT isolation in this study should not,
therefore, weaken the recommendation for smoking ces-
sation for all patients. Other explanations to this point
maybe those individuals who develop respiratory symp-
toms due to more severe disease being more likely to
quit smoking.
Previous studies have produced controversial data
about the presence of P. aeruginosa in isolates, though
they have tended to show that sensitive P. aeruginosa
had higher mortality [28–31]. We found no differences
in mortality between patients with P. aeruginosa, includ-
ing those with MDR strains. In other respiratory
diseases, such as cystic fibrosis or non-cystic fibrosis
bronchiectasis, microbiologic isolation of P. aeruginosa
and MRSA has been shown to have an important role in
disease progression [32–36]. Although there is evidence
that eradication with antibiotic treatment would be benefi-
cial in these diseases, there is no such evidence that simi-
lar benefits would exist for patients with COPD.
The role of antimicrobial treatment remains controversial
in AECOPD. With the exception of patients who require
mechanical ventilation and ICU admission, the benefits of
antibiotic treatment are limited, and are mainly observed in
patients with purulent sputum or in those with AECOPD
graded as type I by the Anthonisen classification [37–41].
The effect of inadequate antibiotic treatment is poorly
understood in patients with AECOPD. In this study, we did
not observe any differences in outcomes between patients
with inadequate and adequate empiric antibiotic treatment.
The predictive factors identified in this study represent
the first step in the development of a prediction model.
To move forward, the potential model will need to
undergo external validation with larger patient cohorts
from multiple centres. We could also apply the results of
internal validation techniques to understand how likely
this model will be replicable to future studies and to
studies at other centres. Bootstrapping techniques were
applied to our data, and the results indicated that the coef-
ficients obtained from the prediction model were quite ro-
bust. Notably, previous P. aeruginosa isolation was the
one factor that the bootstrap analysis indicated might have
limited repeatability in future work. Thus, we opted to re-
move previous P. aeruginosa isolation from the overall
model and include it in a specific multivariate analysis for
P. aeruginosa. In the real-world clinical setting where this
prediction model could be used, previous P. aeruginosa
isolation remains an important clinical characteristic that
can play a substantial role in decision making.
We did not observe differences in the majority of out-
comes when comparing MRCT vs non-MRCT exacerba-
tions. However; length of stay was longer in the MRCT
group. This is an important outcome to be taken into
account to make efforts in predicting and treating these
microorganisms in AECOPD.
Table 4 Significant simple and multiple linear regression analyses of associations of risk of length of hospital stay
Variable Simple Multiplea
β 95% CI P value β 95% CI P value
≥ 2 AECOPD or 1 admission by AECOPD
in the previous year
1.89 0.05 a 3.72 0.044 – – –
Bronchiectasis 1.70 −0.19 a 3.61 0.079 – – –
Long-term oxygen therapy 1.73 −0.19 a 3.66 0.077 – – –
BODEx index 0.89 0.08 a 1.70 0.032 0.81 0.04 a 1.59 0.039
C-reactive protein (mg/dL) −1.56 −3.37 a 0.26 0.092 – – –
PaCO2 2.14 0.34 a 3.94 0.020 – – –
Previous positive sputum culture for
Pseudomonas aeruginosa
5.88 1.83 a 9.92 0.005 – – –
Adequate Empiric Treatment −1.54 −2.86 a − 0.22 0.023 – – –
Invasive mechanical ventilation 8.06 2.91 a 13.21 0.002 5.92 0.82 a 11.02 0.023
Non-invasive mechanical ventilation 3.82 1.45 a 6.19 0.002 3.18 0.84 a 5.53 0.008
MRCT Isolation 3.53 1.19 a 5.88 0.003 3.11 0.84 a 5.37 0.007
Abbreviations: β unstandardized beta coefficient, AECOPD indicates acute exacerbation of chronic obstructive pulmonary disease exacerbation, BODEx body mass
index, airflow obstruction, dyspnoea and exacerbations, CI confidence interval
aAdjusted R2 coefficient of determination = 11.8%
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Our study has some limitations that should be acknowl-
edged. First, the study was carried out at only one centre
in Spain. Second, the small sample limited the analysis of
specific factors per bacterium. There is limited informa-
tion about MRCT isolation in patients with AECOPD,
and where there is, it is mainly for bacteria other than P.
aeruginosa. A confirmation of our results in a large and
well balanced, international cohort of AECOPD is there-
fore desirable. Finally, other limitation of this study was
the use of sputum cultures and the potential difficulty to
distinguish between colonization and infection. However,
we only accepted samples of good quality and we did not
culture those of low quality. In addition this is the usual
way to diagnose lower airway infection in AECOPD in the
majority of studies, given that performing bronchoscopy
in these patients is extremely difficult. Moreover we vali-
dated sputum cultures some years ago in comparison with
bronchoscopic samples [42].
Conclusions
In conclusion, non-current smoking status, ≥2 AECOPD
episodes or ≥ 1 admissions for AECOPD in the previous
year, and low systemic inflammatory response are inde-
pendent risk factors to have an AECOPD caused by a
MRCT. Length of stay was significantly longer in
AECOPD caused by MRCT microorganisms.
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